Sanofi Pasteur believes in a world in which no one suffers or dies from a vaccine-preventable disease.
We Are Focused on Helping to Prevent as Much Influenza Disease As Possible

- Change the influenza conversation from infection to influenza disease and its outcomes
- Increase public awareness of the real impact of flu and the value of flu vaccines
- Grow availability and use of vaccines proven to prevent more disease in higher-risk populations
- Invest in better understanding the impact of current vaccines and development of improved solutions

Vaccinate As Many People as Possible

Deliver the Highest Quality Vaccine(s) Possible

Communications Around Influenza Require the Urgency and Assertiveness Given to Heart Disease and Diabetes

Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction and stroke: a self-controlled case series analysis of national linked datasets from Scotland

Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection

Sanofi Pasteur’s Legacy Of Innovating and Investing Continues

**2018–19 Season: Delivered nearly 70 million doses to the US**
- 22M Fluzone® High-Dose (Influenza Vaccine), representing nearly 2/3 of immunizations in the targeted population
- 12X increase in Flublok® Quadrivalent (Influenza Vaccine) distribution
- Fluzone® Quadrivalent (Influenza Vaccine) remains the most used influenza vaccine brand

**2019–20 Season: Producing 70 million doses to help protect Americans of all ages**
- 10th year of growth for Fluzone High-Dose demand
- Flublok Quadrivalent growth continues